Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial

Table 4 Patient self -evaluation of nausea and vomiting during the 1 ^st CT cycle (ITT population)

	Placebo n = 217	Cocculine n = 214	All patients n = 431	p
Nausea frequency				0.59†
missing data	16	19	35
number of patients evaluable	201	195	396
Number of patients with at least 1 episode of nausea, n (%)	164 (81.6)	155 (79.5)	319 (80.6)
Nausea severity				0.61*
missing data	16	19	35
number of patients evalubale	201	195	396
Median (min-max)	0.56 (0–8.5)	0.58 (0–8.3)	0.56 (0–8.5)
Vomiting frequency				0.56†
missing data	31	19	50
number of patients evaluable	186	170	356
Number of patients with at least 1 episode of vomiting, n (%)	51 (27.4)	42 (24.7)	93 (26.1)
Vomiting severity
missing data	22	25	47	0.44*
number of patients evaluable	195	189	384
Median (min-max)	0.00 (0–7.60)	0.00 (0–5.0)	0.00 (0–7.60)